{"id":"ad26-cov2-s","safety":{"commonSideEffects":[{"rate":"48","effect":"Injection site pain"},{"rate":"38","effect":"Fatigue"},{"rate":"35","effect":"Headache"},{"rate":"27","effect":"Myalgia"},{"rate":"9","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-incompetent adenovirus serotype 26 (Ad26) as a vector to carry the gene encoding the SARS-CoV-2 spike protein into host cells. Once inside cells, the spike protein is produced and presented to the immune system, triggering both cellular and humoral immune responses. This approach generates antibodies and T-cell responses that protect against SARS-CoV-2 infection.","oneSentence":"Ad26.COV2.S is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:22.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT04765384","phase":"PHASE2","title":"A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-08-27","conditions":"COVID-19 Prevention","enrollment":51},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT05037266","phase":"PHASE4","title":"Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-09-20","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT05007080","phase":"PHASE2","title":"A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-09-27","conditions":"Coronavirus Disease-2019 (COVID-19) Prevention","enrollment":304},{"nctId":"NCT04614948","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-11-12","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19","enrollment":31835},{"nctId":"NCT04505722","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-09-07","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol","enrollment":44325},{"nctId":"NCT04436276","phase":"PHASE1, PHASE2","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-07-15","conditions":"Covid-19 Prevention","enrollment":1085},{"nctId":"NCT04999111","phase":"PHASE2","title":"A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-08-06","conditions":"Coronavirus Disease","enrollment":1541},{"nctId":"NCT04908722","phase":"PHASE3","title":"A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-06-18","conditions":"COVID-19 Prevention","enrollment":1609},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05515042","phase":"PHASE2","title":"Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2022-07-25","conditions":"COVID-19","enrollment":694},{"nctId":"NCT05047640","phase":"PHASE3","title":"COVID-19 3rd Dose Vaccine in Transplant Patients","status":"TERMINATED","sponsor":"Giselle Guerra","startDate":"2021-09-14","conditions":"Covid19","enrollment":58},{"nctId":"NCT06360744","phase":"PHASE4","title":"A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines.","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-07-05","conditions":"SARS CoV 2 Infection","enrollment":25},{"nctId":"NCT05409261","phase":"PHASE2","title":"Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-06-02","conditions":"COVID-19, Vaccine Reaction, SARS CoV 2 Infection","enrollment":200},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT04535453","phase":"PHASE2","title":"A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-08-28","conditions":"Healthy","enrollment":635},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT05844202","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention","status":"COMPLETED","sponsor":"Alvea Holdings, LLC","startDate":"2022-06-27","conditions":"Sars-CoV-2 Infection","enrollment":130},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT05081271","phase":"EARLY_PHASE1","title":"COVID-19 Booster Vaccination in Persons With Multiple Sclerosis","status":"TERMINATED","sponsor":"Griffin Hospital","startDate":"2021-10-15","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT05148845","phase":"PHASE3","title":"Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.","status":"UNKNOWN","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2021-11-10","conditions":"SARS CoV 2 Infection","enrollment":500000},{"nctId":"NCT04838795","phase":"PHASE3","title":"Sisonke (Together): OPEN LABEL TRIAL COVID-19","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2021-02-17","conditions":"SARS (Severe Acute Respiratory Syndrome)","enrollment":477102},{"nctId":"NCT05124483","phase":"PHASE2","title":"Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2022-04-21","conditions":"COVID-19","enrollment":600},{"nctId":"NCT05324319","phase":"PHASE2","title":"Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2021-06-15","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT05030974","phase":"PHASE4","title":"RECOVAC Repeated Vaccination Study","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2021-10-21","conditions":"Covid19, Kidney Diseases, Vaccine Response Impaired","enrollment":336},{"nctId":"NCT05178264","phase":"","title":"Transverse Myelitis Related to SARS-CoV-2 Vaccines","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-12-10","conditions":"Vaccine Adverse Reaction","enrollment":580},{"nctId":"NCT04894305","phase":"PHASE1","title":"A Study of Ad26.COV2.S in Healthy Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-05-25","conditions":"Healthy","enrollment":380},{"nctId":"NCT04509947","phase":"PHASE1","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-08-11","conditions":"Healthy","enrollment":250},{"nctId":"NCT04817657","phase":"","title":"Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT04587219","phase":"PHASE2","title":"The Study of \"Gam-COVID-Vac\" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2020-10-22","conditions":"Coronavirus Infection","enrollment":110},{"nctId":"NCT04642339","phase":"PHASE3","title":"Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2020-11","conditions":"Covid19","enrollment":2000},{"nctId":"NCT01375205","phase":"NA","title":"Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-06","conditions":"Atopic Dermatitis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":636,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Janssen COVID-19 Vaccine","JNJ-78436735","JNJ-78436735, VAC31518","Ad26COVS1","JNJ-78436735, Ad26COVS1"],"phase":"phase_3","status":"active","brandName":"Ad26.COV2.S","genericName":"Ad26.COV2.S","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"The Janssen COVID-19 vaccine, also known as Ad26.COV2.S, is a vaccine developed by Janssen Vaccines and Johnson & Johnson for COVID-19, SARS, and other related conditions. It is one of the interventions being studied in clinical trials, including a trial examining its immunogenicity in tuberculosis patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":14,"withResults":11},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}